



The International Pharmaceutical Excipients Council

# Incorporation of Pharmaceutical Excipients into Product Development using Quality-by-Design (QbD)

First Version  
2020

**This document represents voluntary guidance for the excipient industry and the contents, unless otherwise specified, should not be interpreted as regulatory requirements. Alternatives to the approaches in this Guide may be used to achieve an equivalent excipient quality assurance level.**


**This guide was created to help companies understand current expectations on this topic and is not intended for use by third parties to conduct audits. The content of this guide cannot be reproduced without the written authorisation of the IPEC Federation Management Body.**

## FOREWORD

The International Pharmaceutical Excipients Council (IPEC) is an international industry association formed by excipient manufacturers, distributors and end-users. At the current writing, there are regional pharmaceutical excipient industry associations located in the Americas, Europe, Japan, China, and India. IPEC's objective is to contribute to international excipient standards development and harmonization, new excipient development and introduction, and best practice and guide development concerning excipients.

IPEC has three major stakeholder groups;

1. Excipient manufacturers and distributors, defined as suppliers in this document
2. Pharmaceutical manufacturers, defined as users in this document
3. Public health and regulatory authorities



This Guide is intended to be voluntary, to indicate best practice, and to be globally applicable. However, it should be recognized that the rules and regulations applying to excipients will vary from region to region and country to country. In addition, the rules and regulations are continually evolving. It is the responsibility of users of the Guide to determine whether there are any additional legal or regulatory requirements, in addition to the recommendation given in this Guide, applicable to a particular region or country in which they are doing business.

This Guide offers current best practice and voluntary guidance on the incorporation of excipients and excipient variability into Quality-by-Design (QbD) pharmaceutical finished product development programs. It is important that the reader confirms this is the latest version of the guide as found on [www.ipec-federation.org](http://www.ipec-federation.org) or regional IPEC websites.

**NOTE:** Refer to the “International Pharmaceutical Excipient Council Glossary: General Glossary of Terms and Acronyms” for definitions [1]. The first use of a term found in the glossary will be in **BOLD**.

## Table of Contents

<b>FOREWORD</b> .....	<b>1</b>
<b>ACKNOWLEDGEMENTS</b> .....	<b>5</b>
<b>1 INTRODUCTION</b> .....	<b>6</b>
<b>1.1 Purpose</b> .....	<b>6</b>
<b>1.2 Scope</b> .....	<b>6</b>
<b>1.3 Principles Adopted</b> .....	<b>7</b>
<b>2 BACKGROUND AND GENERAL GUIDANCE</b> .....	<b>8</b>
<b>2.1 An introduction to Drug and Drug Product Development</b> .....	<b>8</b>
<b>2.2 Quality-by-Design</b> .....	<b>10</b>
<b>2.3 Excipients</b> .....	<b>15</b>
<b>2.4 Pharmaceutical products</b> .....	<b>18</b>
<b>3 INCORPORATION OF EXCIPIENTS INTO THE FORMULATION</b> .....	<b>20</b>
<b>3.1 Excipient selection</b> .....	<b>20</b>
<b>3.2 Formulation and Process Design and Development</b> .....	<b>21</b>
<b>3.3 Risk assessment</b> .....	<b>21</b>
<b>3.4 Design of Experiments</b> .....	<b>23</b>
<b>3.5 Design Space and Control Strategy</b> .....	<b>23</b>
<b>4 EXCIPIENTS IN QUALITY-BY-DESIGN</b> .....	<b>25</b>
<b>4.1 Introduction</b> .....	<b>25</b>
<b>4.2 Excipient Impact Categorization</b> .....	<b>30</b>
<b>4.3 Critical Material Attributes</b> .....	<b>31</b>
<b>4.4 Analysis of the Design of Experiments (DoE)</b> .....	<b>34</b>
<b>4.5 Scale-up</b> .....	<b>35</b>
<b>5 LIFECYCLE MANAGEMENT</b> .....	<b>36</b>
<b>5.1 Continued monitoring</b> .....	<b>36</b>
<b>5.2 Multivariate Analysis (MVA)</b> .....	<b>36</b>
<b>5.3 Continued product verification</b> .....	<b>37</b>
<b>5.4 Detection of product/excipient drift and out-of-trend results</b> .....	<b>37</b>
<b>5.5 Excipient-related Special Cause Variation in Production</b> .....	<b>37</b>

<b>6 REFERENCES.....</b>	<b>40</b>
<b>ANNEX A Pharmaceutical Development Process.....</b>	<b>43</b>
<b>ANNEX B Kano Analysis.....</b>	<b>45</b>

## Table of Tables

<b>Table 1: The criticality of Lactose Particle Size Distribution in different dose forms .....</b>	<b>32</b>
---	-----------

## Table of Figures

<b>Figure 1 Pharmaceutical Drug Development Timelines .....</b>	<b>8</b>
<b>Figure 2 ICH Quality Roadmap [21].....</b>	<b>11</b>
<b>Figure 3 Reducing Product Variability [21].....</b>	<b>12</b>
<b>Figure 4 Simple Process Capability Model.....</b>	<b>30</b>

## ACKNOWLEDGEMENTS

This guide was developed by the International Pharmaceutical Excipients Council members representatives. IPEC Federation, or in short the Federation, is a global organisation that promotes quality and safety in pharmaceutical excipients. The Federation consists of the five existing regional IPECs: IPEC-Americas, IPEC China, IPEC Europe, IPEC India, IPEC Japan. The representatives who worked on this Guide are listed below:

### *List of Contributors from IPEC-Americas*

Brian Carlin, Ph.D. (Chair), DFE Pharma  
David Schoneker (Vice-Chair), Black Diamond Regulatory Consulting, LLC  
George Collins, Vanderbilt Chemicals LLC  
Ann Gray, Evonik  
David Klug, Sanofi US  
Bretta Lichtenhan, MilliporeSigma  
Lisa Milano, Genentech  
R. Christian Moreton, FinnBrit Consulting  
Meera Raghuram, Lubrizol Advanced Materials, Inc.  
Jerry Schalau, DuPont  
Chandra Sekhar, Chandra V. Sekhar Consulting  
Heather Sturtevant, Johnson & Johnson  
Katherine Ulman, KLU Consulting, LLC  
Priscilla Zawislak, DuPont  
Joseph Zeleznik, IMCD US

### *List of Contributors from IPEC Europe*

Aurelia Defachelles, Roquette  
Bastiaan Dickhoff, DFE Pharma  
Tobias Hess, Budenheim  
Carsten Huettermann, DuPont  
Yasemin Koybasi, Kerry  
Clara Sachwitz, BIOGRUND  
Manuel Streib, Merck Group  
Mike Tobyn, Bristol-Myers Squibb  
Bhushan Thekedar, Clariant  
Kim Verwaest, Johnson & Johnson

### *List of Contributors from IPEC India*

Shraddha Joshi, Evonik